F Horvath

Learn More
OBJECTIVE Our prespecified dose-response analyses of A Very Early Rehabilitation Trial (AVERT) aim to provide practical guidance for clinicians on the timing, frequency, and amount of mobilization following acute stroke. METHODS Eligible patients were aged ≥18 years, had confirmed first (or recurrent) stroke, and were admitted to a stroke unit within 24(More)
To study the efficacy and safety of tolperisone - a centrally acting muscle relaxant with membrane stabilizing activity - in the treatment of stroke-related spasticity. This was a randomized, double-blind, placebo-controlled, multicenter study with parallel groups. Treatment lasted 12 weeks and was started with a titration period of variable length (dose(More)
Sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride (Mydocalm), a centrally active muscle-relaxing agent, were evaluated in a placebo-controlled double-blind clinical trial. A total of 72 healthy young adults balanced by sex were randomized to receive 50 mg or 150 mg tolperisone hydrochloride or placebo t.i.d. for a(More)
  • Sterling J, Bojanic D, Eglen Rm, Heyse S, Strulovici B, Ullman Ef +117 others
  • 2009
general Bossé R, Illy C, Elands J, and Chelsky D Miniaturizing screening: How low can we go today? Drug Discov Today HTS supplement 2000; 42-47 Eglen RM, Reisine T, Roby P, et al The use of AlphaScreen technology in HTS: current status. Current trends in high-throughput screening. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable(More)
  • 1